Topics:

Astellas, Medivation team on prostate Rx

Astellas, Medivation team on prostate Rx

Astellas has partnered with Medivation to co-develop and market the oral anti-androgen, MDV3100. In September, Medivation enrolled patients in the phase III AFFIRM trial, which is evaluating MDV3100 in 1,200 men with castration-resistant prostate cancer who were previously treated with docetaxel (Doxil) chemotherapy.

 
Loading comments...

By clicking Accept, you agree to become a member of the UBM Medica Community.